Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Soon Choi

Internal Medicine Fenton, MI Medical Doctor

NPI 1821088162 CMS profile 841841

2420 Owen Rd, Fenton, MI 48430

Open in the dashboard

General payments

$9,852

435 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Soon Choi of Fenton, MI is reported in the CMS Open Payments database as having received $9,852 across 435 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $694 28
2024 General $1,048 44
2023 General $1,035 43
2022 General $1,208 54
2021 General $2,009 89
2020 General $1,552 74
2019 General $2,307 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Soon Choi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Soon Choi were reported at $694. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Soon Choi Internal Medicine median Middle half National median
2019 $2,307 $159 $48–$570 $163
2020 $1,552 $119 $33–$402 $114
2021 $2,009 $135 $37–$521 $132
2022 $1,208 $141 $42–$496 $149
2023 $1,035 $149 $45–$519 $160
2024 $1,048 $154 $47–$537 $164
2025 $694 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,265 56 payments
  2. Amarin Pharma Inc. $1,146 39 payments
  3. Amgen Inc. $1,036 44 payments
  4. GlaxoSmithKline, LLC. $789 38 payments
  5. AstraZeneca Pharmaceuticals LP $622 30 payments
  6. Pfizer Inc. $513 25 payments
  7. Lilly USA, LLC $492 26 payments
  8. Janssen Pharmaceuticals, Inc $352 13 payments
  9. Gilead Sciences, Inc. $336 15 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $315 14 payments
  11. Other $2,986 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,827 432 payments
  2. Education $25 3 payments
Products named General payments · program years 2019–2025
  1. CREON $1,090 47 payments
  2. LINZESS $961 42 payments
  3. Repatha $669 29 payments
  4. Vascepa Cardiovascular $614 25 payments
  5. Vascepa Hypertriglyceridemia $532 14 payments
  6. TRELEGY ELLIPTA $498 24 payments
  7. Otezla $477 21 payments
  8. Prolia $443 18 payments
  9. FARXIGA $430 20 payments
  10. JARDIANCE $383 21 payments
  11. Other $7,158 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

4,373

Median for Internal Medicine: 777

Drug cost

$722,224

Median for Internal Medicine: $73,373

Branded share of claims

30.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 121 $148,670
Jardiance Empagliflozin Brand 92 $80,661
Januvia Sitagliptin Phosphate Brand 73 $61,754
Vascepa Icosapent Ethyl Brand 141 $53,198
Farxiga Dapagliflozin Propanediol Brand 61 $43,000
Prolia Denosumab Brand 22 $37,445
Trulicity Dulaglutide Brand 25 $25,988
Ozempic Semaglutide Brand 19 $25,086
Janumet Sitagliptin Phos/Metformin Hcl Brand 23 $24,085
Rybelsus Semaglutide Brand 15 $20,935

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$54,440

Of which drugs: $1,529

Medicare patients

240

Average age 80

Services billed

995

180 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 64%
Ischemic heart disease 35%
Osteoporosis 35%
Depression 18%
Alzheimer's or dementia 18%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 31 31 $1,119

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $63
  • Lilly USA, LLC $51
$114 92 —
IBSRELA
  • Ardelyx, Inc. $104
$104 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $97
$97 — —
LINZESS
  • AbbVie, Inc. $79
$79 27 —
CREON
  • AbbVie, Inc. $79
$79 121 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

435 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record